SCHEMBL415391

SCHEMBL415391

CN(Cc1ccccc1N)C(=O)CCCSc1ccc(O)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.40
RAB9A P51151 3/20 0.38
NPC1 O15118 2/20 0.38
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
SLC6A3 Q01959 1/20 0.36
LTB4R2 Q9NPC1 1/20 0.36
HSP90AA1 P07900 1/20 0.35
KCNH2 Q12809 1/20 0.35
HDAC4 P56524 1/20 0.35
BCHE P06276 4/20 0.35
ACHE P22303 4/20 0.35
CHRM2 P08172 1/20 0.35
CHRM1 P11229 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
MTOR P42345 1/20 0.34
THRA P10827 1/20 0.34
THRB P10828 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL419661 0.88 RAB9A (0.43) ALDH1A1RAB9ANPC1KMT2AMEN1
SCHEMBL414300 0.87 BCHE (0.48) ALDH1A1RAB9ANPC1KMT2AMEN1
SCHEMBL415110 0.86 TDP1 (0.48) ALDH1A1RAB9ANPC1KMT2AMEN1
SCHEMBL413187 0.86 L3MBTL1 (0.41) ALDH1A1RAB9ANPC1KMT2AMEN1
SCHEMBL416332 0.86 BCHE (0.49) ALDH1A1RAB9ANPC1KMT2AMEN1
SCHEMBL414368 0.85 ALDH1A1 (0.40) ALDH1A1RAB9ANPC1KMT2AMEN1
SCHEMBL414723 0.85 PLK1 (0.44) ALDH1A1RAB9ANPC1KMT2AMEN1
SCHEMBL413455 0.84 ACHE (0.54) KMT2AMEN1BCHEACHECHRM2
SCHEMBL411317 0.84 NPC1 (0.45) ALDH1A1RAB9ANPC1KMT2ASLC6A2
SCHEMBL416348 0.84 METAP2 (0.43) ALDH1A1KMT2AMEN1TDP1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120022054-A1 NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS LABORATOIRE BIODIM (FR) 2012-01-26 US disclosed
EP-2376431-A1 NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS LABORATOIRE BIODIM (FR) 2011-10-19 EP disclosed
WO-2010066847-A1 NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS CELLVIR (FR) 2010-06-17 WO disclosed
EP-2196453-A1 Novel substituted aryl derivatives, their process of preparation and their therapeutical uses as anti-HIV agents Cellvir (FR) 2010-06-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022054-A1 NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS HAVCR2, MAVS, EIF2AK2 ALDH1A1 455/4885RAB9A 646/4885NPC1 76/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.